Biotricity receives Nasdaq bid price deficiency notice; 180-day cure period to Jan 22, 2025

BIOTRICITY INC.

Closing bid price below $1.00 for 30 consecutive business days triggers Nasdaq Listing Rule 5550(a)(2) deficiency.
Company has until January 22, 2025 to regain compliance with minimum $1.00 closing bid for 10 consecutive days.
If non-compliant by Jan 22, may receive additional 180-day period to cure, subject to other listing standards.
Biotricity intends to monitor bid price and consider available options, including a reverse stock split.
No immediate impact on Nasdaq listing or trading of BTCY common stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.